Skip to main content
Premium Trial:

Request an Annual Quote

Hardy Diagnostics Inks US Distribution Deal With Autobio Diagnostics for SARS-CoV-2 Test

NEW YORK – Medical device manufacturer Hardy Diagnostics announced Wednesday it has partnered with Autobio Diagnostics to distribute its in vitro diagnostic Anti-SARS-CoV-2 Rapid Test in the US.

The rapid one-step lateral flow immunoassay detects IgG and IgM antibodies to SARS-CoV-2 and was developed by Zhengzou, China-based Autobio Diagnostics specifically for determining the possibility that a person may have been infected with the coronavirus, even if there are no symptoms. It uses a finger-prick blood, serum, or plasma specimen and has a 15-minute turnaround time.

Financial and other terms of the partnership were not disclosed.